un Call IMI-2 sur la thématique vaccination & immuno-senescence (healthy aging) vient d’être lancé.
Pr Brigitte Autran, Co-Chair of the UPMC/Pitié-Salpétrière Federative Institute of Research on Immunity-Cancer-Infection (link to the website) since 2009, she is responsible for a Inserm/UPMC research team on Immunity to viruses and vaccines since 2001 (link to the website). She is professor of immunology at the University Pierre et Marie Curie (UPMC) faculty of Medicine since 1994. She has been at the forefront of the immunology of infectious diseases and co-developed since 1984 at the Pitié-Salpétrière hospital a clinical immunology department dedicated to AIDS, transplants and immune-suppressed populations, she is running since 2010. She is a member of the French Comité Technique des Vaccinations (Ministry of Health) since 2003 (link to the website) and of the WHO Global Advisory Committee on Vaccine Safety since 2007 (link to the website), in charge of vaccines in immune-suppressed populations. The scientific career of Prof. Autran was dedicated to the study of virus and vaccine immunity. As one of the pioneers in the fight against AIDS she brought major contributions as the first demonstrations of: i) cellular immunity to HIV, providing rationale for vaccines against HIV; ii) immune reconstitution with anti-retroviral therapies against HIV, opening a new era in the management of AIDS; iii) therapeutic vaccines against HIV, by developing basic, translational and clinical national and international programs, now integrated in the international IAS effort Toward an HIV Cure. Her contributions to vaccine immunity demonstrated the mechanisms of long term memory to vaccines and opened innovative strategies to improve vaccine immunogenicity, particularly in immunosuppressed individuals.
Dr Béhazine Combadière has been pioneer in vaccine immunity and delivery by hair follicular targeting and has brought from concept into clinical trials; this novel needle-free vaccination method. Under the European contract, she coordinates the EU-FP7 project CUT’HIVAC (link to the website) for Cutaneous and Mucosal HIV vaccination (January 2010- December 2014). CUT’HIVAC is a large consortium of 14 European and ICPC (Mozambic and Peru) involved in the development of cutaneous and mucosal vaccination strategies against HIV. B. Combadière has also participated to European projects (FP6) as a work-package leader on “preclinical mice model for vaccine immunogenicity” (MuNanoVac, Mucosal Nanoparticle Vaccines, link to the website). She also participated to the Europrise program (FP6). BehazineCombadire is the head of team “strategies in vaccination and immune memory” (link to the website). The team research is focused on immunology of infectious diseases (HIV, influenza viruses, and Smallpox viruses) and routes of administration of vaccines and patch vaccine development. She is particularly interested in analyzing the molecular and cellular mechanisms of vaccination. She has been awarded as “TEAM 2013” by Fondationpour la RechercheMedicale.
Dr Odile Launay is vice-Chair of the Technical Committee on vaccination (CTV). Odile Launay takes part in the work by the technical Committee on vaccination from the HCSP since 2007, where she is vice-president since 2011. She is a member of the Board of the College of Teachers of infectious diseases (CMIT) and expert at the National Security Agency of Medicines and Health Products (ANSM) and the High Authority of Health. Professor in Infectious Diseases at the University Paris Descartes, hospital doctor in Cochin Hospital in Paris, Odile Launay coordinates the CIC Vaccinology Cochin Pasteur, the only French clinical research center dedicated to vaccinology. It coordinates the National Network of Clinical Investigation Vaccinology (REIVAC) established in 2007 whose mission is to promote clinical research in vaccinology in France in partnership with academic and industrial researchers. Odile Launay is a vaccination expert of specific populations. His expertise in infectious diseases and vaccinology led her to take part in many research with public health institutions including INSERM (Institute of Microbiology and Infectious Diseases), the Pasteur Institute and the National Agency for AIDS research.
Dr Roger Le Grand has been heading the Immuno-Virology Division (link to the website) at the Institute of Emerging Diseases and Innovative Therapies at the Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), France, since 2007. Dr. Le Grand has worked as an expert providing consulting services to several French national research agencies, the French government, the Bill and Melinda Gates Foundation, as well as the WHO. His research interests previously focused on non human primate models of human viral infections for study host/pathogen interactions and prevention of virus transmission. Nowadays, Dr. Le Grand’s research group is developing NHP models for HIV, HBV, Dengue, Yellow Fever and Chikungunya. He is particularly interested in analyzing the molecular and cellular mechanisms that play a role in chronic viral infections as well as emerging viral infections.
Dr Daniel Lévy-Bruhl is a medical epidemiologist, with a Master in Public Health. After having worked as a free-lance consultant for UNICEF and WHO mainly for the Expanded Program on Immunisation and the Control of Diarrhoeal Diseases Program, he joined the Communicable Diseases and Immunisation Unit of the International Children Center in Paris in 1986. His main activities consisted in training activities in epidemiology applied to vaccination, in conducting operational research and in providing expertise regarding vaccination programs to the Ministries of Health of developing countries. In 1997, he joined the French National Institute for Public Health Surveillance (now Santé publique France) where he is co-ordinating, within the Infectious Diseases Direction, the Unit in charge of the activities related to the surveillance and expertise regarding vaccine preventable diseases. The main function of this unit is to monitor the epidemiological impact of the vaccination activities carried out through the National Immunisation Program. The analysis of surveillance and coverage data serves to make recommendations to the Ministry of Health, within the Technical Advisory Board on Immunisation, regarding needed changes in the schedule or in its level of implementation. When a new vaccine is granted a licence, ad hoc analysis is carried out (disease burden studies, mathematical modelling and economic evaluation) to assess the relevancy of its integration in the schedule. The unit is also actively contributing to the expertise for the Ministry of Health regarding large scale health threat control measures (smallpox, SRAS, pandemic influenza…). Recently, the scope of the Unit has been extended to cover surveillance and expertise activities related to non vaccine preventable respiratory infections.
Dr Camille Locht holds currently a position as Research Director at the French National Institute of Health and Medical Research (Inserm) and heads the Center for Infection and Immunity of Lille (link to the website) at the Institut Pasteur de Lille in France. He has obtained his PhD at the Catholic University of Leuven in Belgium in 1984. After 3 post-doctoral years at the National Institute of Allergy and Infectious Disease (USA), where he cloned the pertussis toxin genes, he joined SmithKline – Beecham (now GSK) to help developing acellular pertussis vaccines. In 1989 he was appointed as laboratory chief at the Institut Pasteur de Lille, where he is now the Scientific Director. His research interest is in molecular pathogenesis of respiratory infections, essentially pertussis and tuberculosis, with the long-term aim to develop new vaccines against both diseases. A very powerful molecular typing system for mycobacteria, invented in his laboratory has already reached the market, and a live attenuated nasal pertussis vaccine developed in his laboratory has now completed phase I clinical trials. He has authored close to 250 international publications, several dozens of patents and has obtained several research awards in France.
Dr Frédéric Tangy , PhD, Dr.Sc., is Director of research at CNRS and head of the Viral Genomics and Vaccination laboratory at Institut Pasteur (CNRS URA-3015, link to the website). He made his carreer as a virologist in CNRS and Institut Pasteur. In the recent years, he has developed two research programs : 1) the generation of polyvalent viral attenuated vaccines based on a vector derived from measles vaccine (design of antigens, construction of replicating recombinant vectors, preclinical and clinical development in the field of HIV, dengue and malaria), 2) the mapping of the interactions between viral and host proteins in a systematic way using functional genomic approaches to identify new targets for drugs and new determinants of pathogenicity/attenuation. In 2008 he launched with Armelle Phalipon the international Vaccinology (link to the website) course of Institut Pasteur.
Dr Pierre Verger , has been the assistant director of the South-eastern health regional observatory (Observatoire régional de la santé Paca, link to the website) at Marseille since 2001. As a senior epidemiologist and public health specialist, he is also a member of UMR912 Inserm-IRD-Aix Marseille Université SESSTIM (Sciences Economiques et Sociales de la Santé et Traitement de l’Information Médicale, link to the website). He has 20 years of experience in developing, analyzing and publishing population-based studies in different population groups (general population, students, health professionals, etc.) and on various public health problems. Dr. Pierre Verger has especially invested in SHS research regarding attitudes and practices of general practitioners when caring for various diseases, and implementing prevention activities, especially vaccination.